Company intelligence / Profile preview
Biohaven Ltd.
New Haven, Connecticut, United States of Americabiohaven.com ↗
- Ownership
- Public · BHVN
- Employees
- ~928
- Development stage
- Phase 3
01
Overview
Advancing multiple clinical programs including degrader technology BHV-1300 showing up to 84% reduction in serum IgG, ADC programs in oncology, and TYK2/JAK1 inhibitor for Parkinson's disease
- Therapeutic areas
- PsychiatryImmunologyOncologyRare DiseasesNeurology
- Modalities
- Small moleculesantibody drug conjugates (ADCs)degraders (MoDE™ technology)bispecific molecules
- Industry
- Biotech
02
Drug pipeline
36 assets35 more assets in the full pipeline.
Request access →03
Partnerships
04
Financials
- Market cap
- $2.3B
- Total revenue
- $0
- Enterprise value
- $2.3B
Beyond the preview
Go deeper on Biohaven Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biohaven Ltd..